These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 32153201)

  • 21. Ruxolitinib.
    Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
    Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
    Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients.
    Wei C; Zhang X; Liang D; Yang J; Du J; Yue C; Deng L
    Drug Des Devel Ther; 2021; 15():4875-4883. PubMed ID: 34880598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New Concepts of Treatment for Patients with Myelofibrosis.
    Bose P; Alfayez M; Verstovsek S
    Curr Treat Options Oncol; 2019 Jan; 20(1):5. PubMed ID: 30675650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results.
    González Vicent M; Molina B; González de Pablo J; Castillo A; Díaz MÁ
    Am J Hematol; 2019 Mar; 94(3):319-326. PubMed ID: 30536806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients.
    Khandelwal P; Teusink-Cross A; Davies SM; Nelson AS; Dandoy CE; El-Bietar J; Marsh RA; Kumar AR; Grimley MS; Jodele S; Myers KC
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1122-1127. PubMed ID: 28344057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib.
    Marcuzzi A; Rimondi E; Melloni E; Gonelli A; Grasso AG; Barbi E; Maximova N
    Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
    Przepiorka D; Luo L; Subramaniam S; Qiu J; Gudi R; Cunningham LC; Nie L; Leong R; Ma L; Sheth C; Deisseroth A; Goldberg KB; Blumenthal GM; Pazdur R
    Oncologist; 2020 Feb; 25(2):e328-e334. PubMed ID: 32043777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
    Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
    Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
    Spoerl S; Mathew NR; Bscheider M; Schmitt-Graeff A; Chen S; Mueller T; Verbeek M; Fischer J; Otten V; Schmickl M; Maas-Bauer K; Finke J; Peschel C; Duyster J; Poeck H; Zeiser R; von Bubnoff N
    Blood; 2014 Jun; 123(24):3832-42. PubMed ID: 24711661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruxolitinib treatment for GvHD in patients with myelofibrosis.
    Mori Y; Ikeda K; Inomata T; Yoshimoto G; Fujii N; Ago H; Teshima T
    Bone Marrow Transplant; 2016 Dec; 51(12):1584-1587. PubMed ID: 27721370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study.
    Shiratori S; Fukushima K; Onishi Y; Doki N; Goto T; Okada M; Nakamae H; Maeda Y; Kato K; Ishikawa T; Kondo T; Toyosaki M; Ikeda T; Uchida N; Maki A; Shimada F; Tajima T; Stefanelli T; Teshima T
    Int J Hematol; 2024 Dec; 120(6):705-716. PubMed ID: 39361234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape.
    Shapiro RM; Antin JH
    Expert Rev Hematol; 2020 May; 13(5):519-532. PubMed ID: 32249631
    [No Abstract]   [Full Text] [Related]  

  • 34. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness.
    Mohty M; Holler E; Jagasia M; Jenq R; Malard F; Martin P; Socié G; Zeiser R
    Blood; 2020 Oct; 136(17):1903-1906. PubMed ID: 32756949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
    Jagasia M; Perales MA; Schroeder MA; Ali H; Shah NN; Chen YB; Fazal S; Dawkins FW; Arbushites MC; Tian C; Connelly-Smith L; Howell MD; Khoury HJ
    Blood; 2020 May; 135(20):1739-1749. PubMed ID: 32160294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
    Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E; Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
    Cancer; 2014 Feb; 120(4):513-20. PubMed ID: 24258498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease.
    Algeri M; Becilli M; Locatelli F
    Expert Rev Clin Immunol; 2023; 19(11):1299-1313. PubMed ID: 37606511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease.
    Watson AP; Brunstein CG; Holtan SG
    Case Rep Transplant; 2018; 2018():4539757. PubMed ID: 30519495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.
    Martini DJ; Chen YB; DeFilipp Z
    Oncologist; 2022 Aug; 27(8):685-693. PubMed ID: 35443042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.
    Uygun V; Karasu G; Daloğlu H; Öztürkmen S; Kılıç SÇ; Yalçın K; Çelen SS; Hazar V; Yeşilipek A
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28190. PubMed ID: 31981413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.